DYNAMICS OF IL-12/IL-23 LEVELS IN PSORIASIS PATIENTS TREATED WITH USTEKINUMAB
Abstract
In the treatment of 110 psoriasis patients with a mean PASI index of 27.7±3.2, ustekinumab was administered at a dose of 90 mg subcutaneously according to a specific regimen (6 injections in total), which allowed PASI 100 to be achieved in 91.5% of patients, along with normalization of the main pathogenetic cytokines IL-12 and IL-23 by the end of targeted therapy.
References
1. Bakulev A.L., Samtsov A.V., Sokolovsky E.V. Targeted therapy of psoriasis. Vestnik Dermatologii. 2022;2:42-52.
2. Belova O.V., Arion V.Ya. Immunobiologically active substances isolated from the skin. Vestnik RAMN. 2010;6:8-12.
3. Znamenskaya L.F., Svishchenko S.I. First experience of using ustekinumab in the treatment of psoriasis patients in Russia. 2012;2:48-52.
4. Ketlinsky S.A., Simbirtsev A.S. Cytokines. Saint Petersburg. Foliant. 2008. 345 p.
5. Kruglova L.S., Bakulev A.L., Korotaeva T.V., Lila A.M. Psoriasis. Moscow: GEOTAR-Media. 2022. 328 p.
6. Rakhmatov A.B. Psoriatic disease. Tashkent. 2019. 238 p.
7. Albanesi C, de Pita J, Girolomoni G. Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol. 2007;25:581-588.
8. Boniface K, Blom B, Liu Y. From interleukin-23 to T-helper 17 cells differentiation revisited. Immunol Rev. 2008;226:132-146.
9. Capon F, Meglio P, Szaub J. Sequence variants in the genes for the interleukin-23 receptor and its ligand IL-12B confer protection against psoriasis. Hum Genet. 2007;122:201-206.
10. Kim J, Krueger J. Highly effective new treatments for psoriasis target the IL-23/Type 17 cell autoimmune axis. Ann Rev Med. 2017;68:255-269.
11. Koo J, Marangeli LB, Nakamura M. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol. 2017;31(12):1999-2009.
12. Langrish C, Chen Y, Blumenschein W. IL-23 drives a pathogenic T-cell population that induces autoimmune inflammation. J Exp Med. 2005;201:233-240.
13. Loures M, Aives H, de Moraes A. Association of TNF, IL-12, IL-23 gene polymorphisms and psoriatic arthritis: meta-analysis. Exp Rev Clin Immunol. 2019;15(3):303-313.
14. Luo J, Wu S, Lacy E. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol. 2010;402:797-812.
